Prevention and Management of Antineoplastic-Induced Hypersensitivity Reactions
作者： Kristine M. Zanotti , Maurie Markman
DOI: 10.2165/00002018-200124100-00005
关键词:
摘要: Acute hypersensitivity reactions (HSRs) are an unpredictable and potentially catastrophic complication of treatment with chemotherapeutic agents. Reactions may affect any organ system in the body range widely severity from mild pruritus to systemic anaphylaxis. Certain classes agents, such as taxanes, platinum compounds, asparaginases, epipodophyllotoxins commonly associated HSRs. The clinical characteristics these high risk agents respect HSRs discussed this review.
springer.com
sci-hub.se 参考文章(63)
K Makowska, B Sikorska-Fic, R Rokicka-Milewska, [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase]. Wiadomości lekarskie (Warsaw Poland). pp. 233- 236 ,(1998)
Asselin Bl, The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Advances in Experimental Medicine and Biology. ,vol. 457, pp. 621- ,(1999)
M A Bookman, R F Ozols, S Smolinski, P E Kover, D D Kloth, Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Seminars in Oncology. ,vol. 24, ,(1997)
Barbara L. Asselin, The Three Asparaginases Springer, Boston, MA. pp. 621- 629 ,(1999) , 10.1007/978-1-4615-4811-9_69
Charu Trivedi, Bruce Redman, Lawrence E Flaherty, Omer Kucuk, Wei Du, Lance K Heilbrun, Maha Hussain, None, Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer. ,vol. 89, pp. 431- 436 ,(2000) , 10.1002/1097-0142(20000715)89:2<431::AID-CNCR31>3.0.CO;2-B
M J Piccart, J Klijn, R Paridaens, M Nooij, L Mauriac, R Coleman, M Bontenbal, A Awada, J Selleslags, A Van Vreckem, M Van Glabbeke, Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. Journal of Clinical Oncology. ,vol. 15, pp. 3149- 3155 ,(1997) , 10.1200/JCO.1997.15.9.3149
C J Langer, J C Leighton, R L Comis, P J O'Dwyer, C A McAleer, C A Bonjo, P F Engstrom, S Litwin, R F Ozols, Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. Journal of Clinical Oncology. ,vol. 13, pp. 1860- 1870 ,(1995) , 10.1200/JCO.1995.13.8.1860
E A Eisenhauer, W W ten Bokkel Huinink, K D Swenerton, L Gianni, J Myles, M E van der Burg, I Kerr, J B Vermorken, K Buser, N Colombo, European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology. ,vol. 12, pp. 2654- 2666 ,(1994) , 10.1200/JCO.1994.12.12.2654
M E Trudeau, E A Eisenhauer, B P Higgins, F Letendre, W S Lofters, B D Norris, T A Vandenberg, F Delorme, A M Muldal, Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. Journal of Clinical Oncology. ,vol. 14, pp. 422- 428 ,(1996) , 10.1200/JCO.1996.14.2.422
Michael H. Woo, Lawrence J. Hak, Michael C. Storm, John T. Sandlund, Raul C. Ribeiro, Gaston K. Rivera, Jeffrey E. Rubnitz, Patricia L. Harrison, Bo Wang, William E. Evans, Ching-Hon Pui, Mary V. Relling, Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia Journal of Clinical Oncology. ,vol. 18, pp. 1525- 1532 ,(2000) , 10.1200/JCO.2000.18.7.1525